A5007007404- Cancer Risks and Factors
- Reproductive Biology and Fertility
- Childhood Cancer Survivors' Quality of Life
- Ovarian cancer diagnosis and treatment
- Multiple and Secondary Primary Cancers
- BRCA gene mutations in cancer
- Breast Cancer Treatment Studies
- Global Cancer Incidence and Screening
- Lymphoma Diagnosis and Treatment
- Family Support in Illness
- Ovarian function and disorders
- Renal and related cancers
- Advances in Oncology and Radiotherapy
- Prenatal Screening and Diagnostics
- Birth, Development, and Health
- Chronic Lymphocytic Leukemia Research
- Economic and Financial Impacts of Cancer
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Cancer Treatment and Pharmacology
- Neutropenia and Cancer Infections
- Endometrial and Cervical Cancer Treatments
- Estrogen and related hormone effects
- Reproductive Health and Technologies
- Lung Cancer Treatments and Mutations
European Institute of Oncology
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2025
European School of Oncology
2014-2024
Dana-Farber Cancer Institute
2012-2024
Mylan (Switzerland)
2007-2023
Istituto Oncologico Veneto
2022
Ripamonti
2008-2021
International Breast Cancer Study Group
2016-2021
University of Milan
1992-2020
KU Leuven
2012-2020
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
In patients with aggressive malignancies who are undergoing high-dose chemotherapy, even minimal elevation of troponin I (TnI) is associated late left ventricular dysfunction. The time course the subclinical myocardial damage and its impact on clinical outcome have never been investigated previously.In 703 cancer patients, we measured TnI soon after chemotherapy (early TnI) 1 month later (late TnI). Troponin was considered positive for values > or =0.08 ng/mL. Clinical ejection fraction...
Data on the long-term outcome of children who are exposed to maternal cancer with or without treatment during pregnancy lacking.In this multicenter case-control study, we compared whose mothers received a diagnosis matched women diagnosis. We used health questionnaire and medical files collect data regarding neonatal general health. All were prospectively assessed (by means neurologic examination Bayley Scales Infant Development) at 18 months, 36 both. A cardiac assessment was performed...
EUSOMA (The European Society of Breast Cancer Specialists) is committed to writing recommendations on different topics breast cancer care which can be easily adopted and used by health professionals dedicated the patients with in their daily practice. In 2011, identified management young women as one hot for a consensus among experts was needed. Therefore, society recently organised workshop define such recommendations. Thirteen from disciplines met two days discuss topic. This international...
We questioned the impact of pregnancy on disease-free survival (DFS) in women with history breast cancer (BC) according to estrogen receptor (ER) status.A multicenter, retrospective cohort study which patients who became pregnant any time after BC were matched (1:3) similar ER, nodal status, adjuvant therapy, age, and year diagnosis. To adjust for guaranteed bias, each nonpregnant patient had have a interval at least equal elapsing between diagnosis date conception one. The primary objective...
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, it is remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5,6].
In 2018, the European Society of Gynecological Oncology (ESGO) jointly with for Radiotherapy and (ESTRO) Pathology (ESP) published evidence-based guidelines management patients cervical cancer. Given large body new evidence addressing cancer, three sister societies decided to update these guidelines. The includes topics provide comprehensive on all relevant issues diagnosis treatment in To serve expert panel (27 experts across Europe) ESGO/ESTRO/ESP nominated practicing clinicians who are...
Purpose We have reported previously that after 1-year follow up, gonadotropin-releasing hormone agonist (GnRHa) did not prevent chemotherapy-induced premature ovarian failure (POF) in patients with lymphoma, but may provide protection of the reserve. Here, we report final analysis cohort 5 years up. Patients and Methods A total 129 lymphoma were randomly assigned to receive either triptorelin plus norethisterone (GnRHa group) or alone (control during chemotherapy. Ovarian function fertility...
Prospective data on the risk of recurrence among women with hormone receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking. Download a PDF Research Summary. We conducted single-group trial in which we evaluated temporary interruption adjuvant young previous cancer. Eligible were 42 years age or younger; had stage I, II, III disease; received for 18 30 months; and desired pregnancy. The primary end point was number events (defined...